Giles Platford on Takeda’s 5 Year Deal with WFH for The Humanitarian Aid Program!
Giles Platford, President, Plasma-Derived Therapies Business Unit at Takeda and Chair of the Global Executive Board at PPTA, reposted from World Federation of Hemophilia on LinkedIn:
”I’m proud to share this important milestone: Takeda has renewed its 5-year agreement with the WFH and WFH_USA—furthering our support for the WFH Humanitarian Aid Program!
Together with other partners, we are working to expand access, drive equity, and change lives for people living with inherited bleeding disorders globally.”
Quoting World Federation of Hemophilia‘s post:
”The WFH and WFH USA are pleased to announce that Takeda has signed a 5-year agreement renewal with the WFH Humanitarian Aid Program from 2026 to 2030!
The agreement is for the donation of treatment product, as well as a financial commitment to cover it’s handling, storage and shipping. Learn more.”
Stay updated with Hemostasis Today.
-
Apr 30, 2026, 16:19Ifeanyichukwu Ifechidere: Coagulation Fundamentals for Result Interpretation in Clinical Practice
-
Apr 30, 2026, 16:19David McIntosh: Plasma Medicines for All with United Plasma Action
-
Apr 30, 2026, 15:56Benjamin Spurgeon: What’s next for Platelet Function Testing?
-
Apr 30, 2026, 15:38Ahvie Herskowitz: Is It Iron or ‘Oxidized Rust’? – A New Predictor of Aging.
-
Apr 30, 2026, 15:01Neil Morgan: New Collaborative Research Review on Large‐Scale Genetic Analysis in the Bleeding Disorders Community
-
Apr 30, 2026, 14:52Neema Ngugi: Understanding the D-Dimer Test – A Key Tool in Detecting Blood Clots
-
Apr 30, 2026, 14:45Steven Brown: Contributing to AMSSM CRN Orthobiologics Research on PRP in Muscle Injury and Tendinopathy
-
Apr 30, 2026, 14:33Abdul Mannan: The Clinical Pattern That Should Make You Think of VEXAS
-
Apr 30, 2026, 14:28Jennifer Le Mac: How the Immune System Shapes Venous Thrombosis